Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Rises By 2,400.0%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,500 shares, a growth of 2,400.0% from the October 31st total of 100 shares. Based on an average daily trading volume, of 15,200 shares, the short-interest ratio is presently 0.2 days.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABSW remained flat at $0.07 during trading hours on Thursday. SAB Biotherapeutics has a 12 month low of $0.01 and a 12 month high of $0.19. The business has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.04.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.